Inventor · disambiguated record
Matthias Steger
Also filed as: STEGER MATTHIAS
10 granted patents·3 pending applications·142 citations·filing 2002–2022
86Inventor score
Files withENDOGENA THERAPEUTICS INC8HOFFMANN LA ROCHE2ACTELION PHARMACEUTICALS AG1ACTELION PHARMACEUTICALS LTD1FRETZ HEINZ1
Top patents by PatentIndex Score
13 records- 0195US6867205B2Pyridine and pyrimidine derivativesHOFFMANN LA ROCHE·Filed 2003·Granted Mar 15, 2005·103 cites·18 claims
- 0293US7022718B2Pyridine and pyrimidine derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Apr 4, 2006·32 cites·16 claims
- 0389US11844755B2Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2022·Granted Dec 19, 2023·1 cites·12 claims
- 0482US11541039B2Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2020·Granted Jan 3, 2023·1 cites·24 claims
- 0573US10807973B2Compounds for use as therapeutically active substances in the treatment of retinal diseasesENDOGENA THERAPEUTICS INC·Filed 2018·Granted Oct 20, 2020·1 cites·40 claims
- 0671US10752593B2Compounds for use as therapeutically active substances in the treatment of retinal diseasesENDOGENA THERAPEUTICS INC·Filed 2018·Granted Aug 25, 2020·1 cites·38 claims
- 0762US12195452B2N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Granted Jan 14, 2025·0 cites·19 claims
- 0854US7067549B2Pyrrolidone carboxamidesACTELION PHARMACEUTICALS AG·Filed 2002·Granted Jun 27, 2006·3 cites·9 claims
- 0954US2023365545A1New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1049US2023322749A1New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epitheliumENDOGENA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1144US7727979B2Guanidine derivatives and their use as neuropeptide FF receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2004·Granted Jun 1, 2010·0 cites·18 claims
- 1243US2022089547A1Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseasesENDOGENA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1338US8273740B22-sulfanyl-benzoimidazol-1-yi-acetic acid derivatives as CRTH2 antagonistsFRETZ HEINZ·Filed 2005·Granted Sep 25, 2012·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Matthias Steger files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →